Pharmasset
Setback for Gilead hep C candidate
February 20, 2012Research and Development, Sales and Marketing ELECTRON, GS-7977, Gilead, Pharmasset
Gilead’s investigational hepatitis C drug has been dealt a blow after patients suffer relapses in a mid-stage trial. In the …
Gilead aims for hep C lead with Pharmasset acquisition
November 22, 2011Research and Development Gilead, HCV, Pharmasset, Victrelis, hepatitis C
Gilead Sciences is to buy Pharmasset for $11 billion in a bid to become a leader in hepatitis C treatment.The …
Contract research news in brief
January 5, 2011Research and Development Accel Synthesis, Almac, Bioanalytical Systems, Caliper Life Sciences, Cambridge Research & Instrumentation, Critical Path Services, Pharmasset, ReSearch Pharmaceutical Services, ResourcingPoint, Warburg Pincus
Private equity firm Warburg Pincus buys RPS for $227 million, plus updates from BASi, Almac, Caliper, and Critical Path Services/Accel …
